These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 8625251

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, Bilchik AJ.
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Therapy of metastatic medullary thyroid gland carcinoma with the somatostatin analog octreotide].
    Frank-Raue K, Raue F, Ziegler R.
    Med Klin (Munich); 1995 Feb 15; 90(2):63-6. PubMed ID: 7708002
    [Abstract] [Full Text] [Related]

  • 26. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK, Reubi JC, Horisberger U, Moertel CG, Rubin J, Charboneau JW.
    Yale J Biol Med; 1992 Feb 15; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide].
    Rischke HC, Staib-Sebler E, Mose S, Adams SW, Herrmann G, Böttcher HD, Lorenz M.
    Dtsch Med Wochenschr; 1999 Feb 19; 124(7):182-6. PubMed ID: 10093577
    [Abstract] [Full Text] [Related]

  • 29. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.
    Bajetta E, Zilembo N, Di Bartolomeo M, Di Leo A, Pilotti S, Bochicchio AM, Castellani R, Buzzoni R, Celio L, Dogliotti L.
    Cancer; 1993 Nov 15; 72(10):3099-105. PubMed ID: 7693327
    [Abstract] [Full Text] [Related]

  • 30. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.
    Ann Oncol; 2000 Sep 15; 11(9):1127-30. PubMed ID: 11061606
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management.
    Claure RE, Drover DD, Haddow GR, Esquivel CO, Angst MS.
    Can J Anaesth; 2000 Apr 15; 47(4):334-7. PubMed ID: 10764178
    [Abstract] [Full Text] [Related]

  • 33. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K.
    Drug Des Devel Ther; 2015 Apr 15; 9():5075-86. PubMed ID: 26366058
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.
    Ozkan E, Tokmak E, Kucuk NO.
    Ann Nucl Med; 2011 Jul 15; 25(6):425-31. PubMed ID: 21476058
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
    Turner GB, Johnston BT, McCance DR, McGinty A, Watson RG, Patterson CC, Ardill JE.
    Gut; 2006 Nov 15; 55(11):1586-91. PubMed ID: 16556667
    [Abstract] [Full Text] [Related]

  • 38. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide.
    Lupoli G, Cascone E, Arlotta F, Vitale G, Celentano L, Salvatore M, Lombardi G.
    Cancer; 1996 Sep 01; 78(5):1114-8. PubMed ID: 8780551
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K.
    Ann Oncol; 2001 Sep 01; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.